Sonnet BioTherapeutics Holdings, Inc. Gains 42.19%
Wed, Nov 05, 2025 at 07:07 PM
Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ) rocketted at $4.55, a gain of 42.2%. The stock got featured on our News Catalysts scanner on Fri, Oct 17, 2025 at 03:01 AM in the 'MISCELLANEOUS' category. From Wed, Oct 22, 2025, the stock recorded 50.00% Up Days and 45.45% Green Days
The stock spiked on Mon, Oct 27, 2025 at $5.85 with a volume of 1M+.
About Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ)
Sonnet BioTherapeutics Holdings Inc is a biotechnology company engaged in the development of biologic drugs focused on human antibody binding technology. The firm's pipeline products include SON-080 (low-dose IL-6), SON-081 (low dose IL-6), SON-1010 (IL12-FHAB), and others.
Top 10 Gainers:
- MMTec, Inc. (MTC:NASDAQ), 626.97%
- Anbio Biotechnology (NNNN:NASDAQ), 57.48%
- Solid Power, Inc. (SLDP:NASDAQ), 51.56%
- Entravision Communications Corporation (EVC:NYSE), 43.94%
- SMX (Security Matters) Public Limited Company (SMX:NASDAQ), 43.54%
- Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ), 42.19%
- Lunai Bioworks Inc Com (LNAI:NASDAQ), 40.29%
- Top Win International Limited (SORA:NASDAQ), 39.15%
- NeuroPace, Inc. (NPCE:NASDAQ), 38.09%
- Lemonade, Inc. (LMND:NYSE), 34.21%